Mammographic density and interval cancers in mammographic screening: Moving towards more personalized screening

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 1,08 MB, PDF-dokument

Purpose: The European Society on Breast Imaging has recommended supplemental magnetic resonance imaging (MRI) every two to four years for women with mammographically dense breasts. This may not be feasible in many screening programs. Also, the European Commission Initiative on Breast Cancer suggests not implementing screening with MRI. By analyzing interval cancers and time from screening to diagnosis by density, we present alternative screening strategies for women with dense breasts. Methods: Our BreastScreen Norway cohort included 508 536 screening examinations, including 3125 screen-detected and 945 interval breast cancers. Time from screening to interval cancer was stratified by density measured by an automated software and classified into Volpara Density Grades (VDGs) 1–4. Examinations with volumetric density ≤3.4% were categorized as VDG1, 3.5%–7.4% as VDG2, 7.5%–15.4% as VDG3, and ≥15.5% as VDG4. Interval cancer rates were also determined by continuous density measures. Results: Median time from screening to interval cancer was 496 (IQR: 391–587) days for VDG1, 500 (IQR: 350–616) for VDG2, 482 (IQR: 309–595) for VDG3 and 427 (IQR: 266–577) for VDG4. A total of 35.9% of the interval cancers among VDG4 were detected within the first year of the biennial screening interval. For VDG2, 26.3% were detected within the first year. The highest annual interval cancer rate (2.7 per 1000 examinations) was observed for VDG4 in the second year of the biennial interval. Conclusions: Annual screening of women with extremely dense breasts may reduce the interval cancer rate and increase program-wide sensitivity, especially in settings where supplemental MRI screening is not feasible.

OriginalsprogEngelsk
TidsskriftBreast
Vol/bind69
Sider (fra-til)306-311
Antal sider6
ISSN0960-9776
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
CIL, SH, KL and ML have no conflicts of interest directly related to this work. CIL has received personal fees from Grail for service on a data and safety monitoring board, personal fees from the ACR for journal editorial board work, and textbook royalties from McGraw-Hill, Oxford University Press, and UpToDate, all outside the submitted work. SH is head of Breast Screen Norway. She has a fixed position at the Cancer Registry of Norway independent of the job as the leader.

Publisher Copyright:
© 2023

ID: 370205967